Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

NCT00632203 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Adenocarcinoma
Carcinoma, Large Cell
Carcinoma, Squamous Cell

Interventions

DRUG: Temozolomide

Sponsor

Merck Sharp & Dohme LLC